Biotoxtech Co., Ltd.

KOSDAQ:A086040 Stock Report

Market Cap: ₩91.6b

Biotoxtech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biotoxtech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth25.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Is Biotoxtech (KOSDAQ:086040) A Risky Investment?

May 06
Is Biotoxtech (KOSDAQ:086040) A Risky Investment?

Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)

Mar 28
Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)

Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?

Feb 20
Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?

Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?

Jan 24
Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?

We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings

Dec 27
We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings

Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?

Nov 30
Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotoxtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A086040 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202332,631-4,878-21,121-16,238N/A
9/30/202334,216-5,408-33,111-16,485N/A
6/30/202336,638-2,487-42,163-11,788N/A
3/31/202337,006199-36,383-3,235N/A
12/31/202237,2921,278-32,094-1,309N/A
9/30/202236,2635,684-19,5442,709N/A
6/30/202235,4615,910-8,2662,006N/A
3/31/202233,9766,462-4,9583,010N/A
12/31/202132,7176,832-3,6104,346N/A
9/30/202131,1203,526-2,9703,917N/A
6/30/202128,5702,6335076,379N/A
3/31/202127,2893,550-2254,638N/A
12/31/202026,4292,6142,0244,564N/A
9/30/202026,3064,2374602,723N/A
6/30/202025,9672,4262,6342,792N/A
3/31/202025,679-1,4141,9022,571N/A
12/31/201925,854-1,4829561,444N/A
9/30/201922,105-4,9132,8793,492N/A
6/30/201923,979-1,5481,2621,869N/A
3/31/201926,632243,2473,958N/A
12/31/201827,2454,1317313,061N/A
9/30/201831,5675,2611324,068N/A
6/30/201829,9853,7351,8546,294N/A
3/31/201827,0594,887-124,422N/A
12/31/201725,5651,3922,6116,024N/A
9/30/201724,3302,115N/A5,215N/A
6/30/201723,9921,966N/A6,050N/A
3/31/201723,1961,584N/A5,932N/A
12/31/201622,2571,045N/A5,283N/A
9/30/201620,404-1,173N/A2,586N/A
6/30/201618,932-1,942N/A1,038N/A
3/31/201617,932-2,873N/A-608N/A
12/31/201516,676-3,905N/A-798N/A
9/30/201515,384-3,790N/A-1,808N/A
6/30/201515,044-4,539N/A-2,794N/A
3/31/201514,815-4,534N/A-1,581N/A
12/31/201415,088-4,528N/A-2,047N/A
9/30/201415,833-3,183N/A-1,245N/A
6/30/201415,864-2,593N/A-2,233N/A
3/31/201416,015-2,084N/A-811N/A
12/31/201317,272-83N/A-218N/A
9/30/201317,3921,022N/A-248N/A
6/30/201317,9281,510N/A1,439N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A086040's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if A086040's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A086040's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A086040's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A086040's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A086040's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.